Immunological biomarkers predict HIV-1 viral rebound after treatment interruption-Reference-Cited by-同舟云学术

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

Published:2015-10-09 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Hurst Jacob,Hoffmann Matthias,Pace Matthew,Williams James P.,Thornhill John,Hamlyn Elizabeth,Meyerowitz Jodi,Willberg Chris^ORCID,Koelsch Kersten K.,Robinson Nicola,Brown Helen,Fisher Martin,Kinloch Sabine,Cooper David A.,Schechter Mauro,Tambussi Giuseppe,Fidler Sarah,Babiker Abdel,Weber Jonathan,Kelleher Anthony D.,Phillips Rodney E.,Frater John

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms9495.pdf

Reference36 articles.

1. Palella, F. J. J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 338, 853–860 (1998).

2. Wada, N. et al. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 28, 257–265 (2014).

3. Samji, H. et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE 8, e81355 (2013).

4. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).

5. Stöhr, W. et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 8, e78287 (2013).

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size;JCI Insight;2024-07-09

2. Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod;Frontiers in Immunology;2024-06-24

3. HIV-1 controllers possess a unique CD8+ T-cell activation phenotype and loss of control is associated with increased expression of exhaustion markers;2024-04-12

4. Viral rebound occurrence immediately after drug discontinuation involving neither drug resistance nor latent reservoir;Journal of Theoretical Biology;2024-04

5. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation;JCI Insight;2024-02-08